Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rxo (RXO) Non-Current Debt (2022 - 2025)

Historic Non-Current Debt for Rxo (RXO) over the last 4 years, with Q4 2025 value amounting to $387.0 million.

  • Rxo's Non-Current Debt rose 1025.64% to $387.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $387.0 million, marking a year-over-year increase of 1025.64%. This contributed to the annual value of $387.0 million for FY2025, which is 1025.64% up from last year.
  • Latest data reveals that Rxo reported Non-Current Debt of $387.0 million as of Q4 2025, which was up 1025.64% from $387.0 million recorded in Q3 2025.
  • In the past 5 years, Rxo's Non-Current Debt ranged from a high of $451.0 million in Q4 2022 and a low of $6.0 million during Q3 2022
  • Over the past 4 years, Rxo's median Non-Current Debt value was $387.0 million (recorded in 2025), while the average stood at $367.0 million.
  • In the last 5 years, Rxo's Non-Current Debt soared by 741666.67% in 2023 and then tumbled by 2217.29% in 2024.
  • Over the past 4 years, Rxo's Non-Current Debt (Quarter) stood at $451.0 million in 2022, then dropped by 21.06% to $356.0 million in 2023, then decreased by 1.4% to $351.0 million in 2024, then rose by 10.26% to $387.0 million in 2025.
  • Its Non-Current Debt was $387.0 million in Q4 2025, compared to $387.0 million in Q3 2025 and $387.0 million in Q2 2025.